Showing results (81-90 of 94) with videos related to

Sort By:
Pageof 10
Archives of Internal Medicine|March 16, 2011
Bupropion for smoking cessation in patients with acute coronary syndromeDavid Planer, Ishay Lev, Yair Elitzur, et al.
Biological Imaging|March 22, 2024
Moment-based metrics for molecules computable from cryogenic electron microscopy imagesAndy Zhang, Oscar Mickelin, Joe Kileel, et al.
Plos One|March 3, 2012
The effect of prolonged physical activity performed during extreme caloric deprivation on cardiac functionDavid Planer, David Leibowitz, Amir Hadid, et al.
The Breast Journal|November 13, 2008
Beginning IVF treatments after age 30 increases the risk of breast cancer: results of a case-control studyDaniela Katz, Ora Paltiel, Tamar Peretz, et al.
Neuropsychiatric Disease and Treatment|May 14, 2026
Clinical Benefit and Risk Profile of TV-46000 for Patients with Schizophrenia as Assessed by Number Needed to Treat and Number Needed to HarmLeslie Citrome, Kelli R Franzenburg, Mark Suett, et al.
CNS Drugs|July 29, 2025
Safety Outcomes with the Long-Acting Subcutaneous Antipsychotic TV-46000 in Schizophrenia: A Post Hoc Analysis of Behavioral, Neuromotor, Endocrine, and Cardiometabolic Outcomes from Two Phase 3 StudiesChristoph U Correll, Helena Knebel, Eran Harary, et al.
CNS Drugs|November 21, 2025
Effects of Long-Term Treatment with TV-46000 on Symptom Improvement Over Time in Stabilized Patients with SchizophreniaJohn M Kane, Orna Tohami, Kelli R Franzenburg, et al.
Experimental Diabetes Research|August 2, 2011
Obesity and blood pressure in 17-year-old offspring of mothers with gestational diabetes: insights from the Jerusalem Perinatal StudyMeytal Avgil Tsadok, Yechiel Friedlander, Ora Paltiel, et al.
Annals of Epidemiology|February 3, 2009
Birth weight of offspring, maternal pre-pregnancy characteristics, and mortality of mothers: the Jerusalem perinatal study cohortYechiel Friedlander, Orly Manor, Ora Paltiel, et al.
CNS Drugs|July 2, 2024
A Long-Term Safety and Tolerability Study of TV-46000 for Subcutaneous Use in Patients with Schizophrenia: A Phase 3, Randomized, Double-Blinded Clinical TrialJohn M Kane, Roy Eshet, Eran Harary, et al.
Pageof 10